Section 4: Clinical Pharmacy Services

4CPS-286

EARLY IMPACT OF COVID ON THE ACTIVITY OF A CLINICAL RESEARCH ONCOLOGY PHARMACY UNIT AT A TERTIARY CARE HOSPITAL

4CPS-285

MULTIDISCIPLINARY ORAL THERAPY OUTPATIENT CLINIC: AN ITALIAN SINGLE CENTRE EXPERIENCE

4CPS-284

TREATMENT OF CYCLIN INHIBITOR INDUCED NEUTROPENIA: IMPACT ON PROGRESSION FREE SURVIVAL

4CPS-283

ONCOHAEMATOLOGICAL PHARMACEUTICAL CARE CONSULTATION. IS THE INFORMATION ON THE EUROPEAN PUBLIC ASSESSMENT REPORT OF DRUGS ENOUGH?

4CPS-282

EPIDEMIOLOGY AND CLINICAL COURSE OF PATIENTS WITH CANCER DIAGNOSED WITH SARS-COV-2 INFECTION

4CPS-281

HIGH DOSE METHOTREXATE IN PEDIATRIC OSTEOSARCOMA PATIENTS: EFFECTIVENESS AND SAFETY.

4CPS-280

BENEFITS OF PHARMACOKINETIC ESTIMATION OF METHOTREXATE LEVELS IN PAEDIATRIC OSTEOSARCOMA PATIENTS

4CPS-279

CANCER PAIN MANAGEMENT APPROACH CONSIDERING POTENTIAL DRUG INTERACTIONS IN PATIENTS RECEIVING ORAL ANTITUMOUR TREATMENT

4CPS-278

EFFECTIVENESS AND SAFETY OF CISPLATIN PLUS GEMCITABINE IN METASTATIC BREAST CANCER

4CPS-277

CETUXIMAB VERSUS BEVACIZUMAB IN METASTATIC COLORECTAL CANCER: A COMPARATIVE EFFECTIVENESS AND PATIENT REPORTED OUTCOMES MULTI-COHORT STUDY

4CPS-276

ATEZOLIZUMAB IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY REAL WORLD DATA STUDY.

4CPS-275

EFFICACY AND SAFETY OF TRIFLURIDINE/TIPIRACIL IN PATIENTS WITH METASTATIC COLORECTAL CANCER: REAL WORLD DATA

4CPS-274

REAL WORLD EFFECTIVENESS OF PALBOCICLIB AND RIBOCICLIB IN WOMEN WITH METASTATIC BREAST CANCER.

4CPS-273

DOES AGE REALLY MATTERS ON THE PREVALENCE OF DRUG-DRUG INTERACTIONS WITH ENDOVENOUS CHEMOTHERAPY?

4CPS-272

PHARMACIST ROLE IN HEALTH OUTCOME OF VD-PACE SAVAGE REGIMEN IN AN ADULT FEMALE PATIENT WITH RARE RELAPSED AND REFRACTORY IgD LAMBDA MULTIPLE MYELOMA

Pages